SCHEMBL14112142

SCHEMBL14112142

O=C(NCc1ccccc1F)N1CCC(N2CCC(c3ccccc3)CC2)C1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CYP2C9 P11712 1/20 0.48
▸ EPHX2 P34913 1/20 0.48
▸ CYP2J2 P51589 1/20 0.48
▸ LMNA P02545 2/20 0.47
▸ MAPK8 P45983 1/20 0.46
▸ NPC1 O15118 2/20 0.46
▸ TP53 P04637 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ GRIN2B Q13224 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ SLC18A3 Q16572 1/20 0.43
▸ HRH3 Q9Y5N1 1/20 0.43
▸ PKM P14618 1/20 0.43
▸ CCR2 P41597 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14112121 0.87 MAPK8 (0.50) CYP2C9EPHX2CYP2J2LMNAMAPK8
SCHEMBL14112120 0.85 HRH3 (0.59) NPC1TP53RAB9ASMN1; SMN2MEN1
SCHEMBL14112140 0.85 ALDH1A1 (0.58) NPC1TP53RAB9ASMN1; SMN2MEN1
SCHEMBL14112130 0.85 GRIN2B (0.65) CYP2C9EPHX2CYP2J2NPC1RAB9A
SCHEMBL14112128 0.82 EPHX2 (0.60) CYP2C9EPHX2CYP2J2MAPK8
SCHEMBL4071469 0.81 TUBB4A (0.53) CYP2C9EPHX2NPC1TP53RAB9A
SCHEMBL14112119 0.81 NPC1 (0.55) LMNAMAPK8NPC1TP53RAB9A
SCHEMBL14112113 0.81 CCR2 (0.67) CCR2
SCHEMBL1575388 0.78 HRH3 (0.62) KDM4EMEN1ALDH1A1KMT2AHRH3
SCHEMBL14207996 0.78 NPC1 (0.42) LMNAMAPK8NPC1TP53RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8754107-B2 Aminopyrrolidines as chemokine receptor antagonists ABBVIE INC. (US) 2014-06-17 — — US disclosed
US-8754107-B2 Aminopyrrolidines as chemokine receptor antagonists ABBVIE INC. (US) 2014-06-17 — — US disclosed
US-20080176883-A1 Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone ABBVIE INC. 2008-07-24 — — US disclosed
US-20080176883-A1 Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone ABBVIE INC. 2008-07-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176883-A1 Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone MIF, CCL5, CCR2 CYP2C9 1750/4885EPHX2 2659/4885CYP2J2 337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback